Back to search

Article

A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control

2023-11-17

Abstract excerpt

Accumulating data from several large, placebo-controlled studies suggests that sodium-glucose transporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 receptor (GLP-1) receptor agonists offer therapeutic benefits in the management of cardiovascular diseases, regardless of the patient’s diabetic status. In addition to their effects on glucose excretion, SGLT2 inhibitors have a positive impact on systemic metab...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
495cbf21-241d-5d13-8d56-f666cf2bd329
DOI
10.22541/au.170022092.29999283/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic ControlDOI 10.22541/au.170022092.29999283/v1
Select a neighboring publication to make it the new centre.